Product
OT-A201
1 clinical trial
2 indications
Indication
Hematological MalignancyIndication
Solid TumorClinical trial
A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 as Monotherapy and in Combination Therapy in Patients With Selected Hematological Malignancies and Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01